Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAequs

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang

      Net Sales are expected to increase by 10.5 percent Y-o-Y (up 1.9 percent Q-o-Q) to Rs 2,847.5 crore, according to Nirmal Bang.

    • Alkem Laboratories reports strong numbers in Q3; highlights of analyst call

      In the US market, the company is planning to file 12-15 products, and launch lower double digit products every year going ahead.

    • Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities

      Net Sales are expected to increase by 3.1 percent Y-o-Y (up 15.1 percent Q-o-Q) to Rs. 1,920 crore, according to HDFC Securities.

    • Global brokerages upgrade these 6 stocks to buy post Q4 results

      Global brokerage houses have upgraded a few stocks, highlighting robust Q4 FY18 results. Moneycontrol takes a look at six such stocks which have seen a ratings upgrade

    • Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities

      Net Sales are expected to increase by 12.7 percent Y-o-Y (down 19 percent Q-o-Q) to Rs. 1,410 crore, according to HDFC Securities.

    • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

      Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

    • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

      As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

    • Alkem Q4 PAT may dip 42.8% to Rs 133.6 cr: ICICI Securities

      Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 16.5 percent Y-o-Y) to Rs 1331.5 crore, according to ICICI Securities. Alkem to report net profit at 133.6 crore down 42.8% quarter-on-quarter.

    • Alkem Labs Q3 PAT may dip 27% to Rs 210 cr: HDFC Securities

      Net Sales are expected to decrease by 11.4 percent Q-o-Q (up 13.9 percent Y-o-Y) to Rs 1450 crore, according to HDFC Securities.

    • Alkem Q3 PAT may dip 28.5% to Rs 202.3 cr: ICICI Securities

      Net Sales are expected to decrease by 12.5 percent Q-o-Q (up 12.5 percent Y-o-Y) to Rs 1433.9 crore, according to ICICI Securities.

    • See FY17 margin at 17% with downside pressure: Alkem Labs

      The company will work towards increasing volumes in the gastro-intestinal, anti-diabetic and cardio segments, among others, to overcome margin pressures due to industry headwinds, says Prabhat Agrawal, CEO of Alkem Laboratories.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347